I think you can take the company's word for it whe

I think you can take the company's word for it when they say that the indications that the term sheet covers are "locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis."

Nothing about oral mucositis, whether someone wants to conflate the mouth and throat that develop inflammation and sores from chemo and radiation with disease syndromes of the intestinal tract which are probably auto-immune disorders. (an absurd conflation)

Once again, here is a link to the press release. It is short. It spells out what the term sheet covers. I have stated this in words of one and two syllables so that there can be no cause for confusion, even by non-native English speakers.
It DOES NOT COVER ORAL MUCOSITIS.

http://www.ipharminc.com/press-release/2019/5...igmoiditis

But I can certainly see why bashers would want to try to muddy the waters. They might want to convince gullible individuals that this must be the only deal afoot at the moment. That is not true.
We have no way to know what the company is doing, but it is certainly illogical to assume that they would abandon efforts to partner on Brilacidin-OM, when they are so close to doing a relatively inexpensive, and quick, Phase 3 clinical trial for that formulation, which could become the ONLY FDA-approved treatment for that life-threatening syndrome.